(124 days)
The L-Varlock Lumbar Cage is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s).
L-Varlock Lumbar implants are to be used with autogenous bone graft and implanted via an open posterior approach. L-Varlock Lumbar implant is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.
L-Varlock Lumbar Cage is implanted via a posterior approach and supplemented by posterior fixation. Two devices are used. Main features of the L-Varlock lumbar cage are:
- Different heights for accurate enlargement of the foramina .
- Different widths and lengths to achieve excellent stability at the instrumented level . while preserving the patient's anatomy.
- Large graft space to achieve good bony fusion .
- Large cortical interface to ensure a good bony fusion. .
- Toothed outer walls prevent implant back out. ●
- The rounded geometry of the anterior end of the cage avoids damage to the anterior vascular structures.
Materials:
L-Varlock lumbar Cages are manufactured from titanium alloy (Ti6Al4V-Eli, ASTM norm F136).
Function:
Lumbar interbody cages are one of the treatment options for low back pain.
Here's an analysis of the L-Varlock Lumbar Cages based on the provided 510(k) summary, specifically focusing on acceptance criteria and study details:
1. Acceptance Criteria and Reported Device Performance
| Acceptance Criteria Category | Specific Criteria/Standard | Reported Device Performance |
|---|---|---|
| Mechanical Performance | ASTM F2077 | Meets required criteria. |
| ASTM F2267 | Meets required criteria. |
2. Sample Size and Data Provenance
- Test Set Sample Size: Not explicitly stated. The document refers to "tests performed according to ASTM F2077/F2267." These standards often specify minimum sample sizes for mechanical testing.
- Data Provenance: Not explicitly stated as "country of origin." However, the tests are conducted according to ASTM (American Society for Testing and Materials) standards, which are internationally recognized, implying a general engineering/materials testing context rather than a clinical dataset. The nature of the tests (mechanical) indicates they are laboratory-based, not patient-data driven, and thus are "prospective" in the sense of being planned experiments, not retrospective analysis of clinical data.
3. Number of Experts and Qualifications for Ground Truth
- Not Applicable. This document describes the mechanical testing of a medical device (lumbar cage), not a diagnostic algorithm or image analysis tool that would require expert-established ground truth. The "ground truth" for mechanical testing is defined by the parameters and limits set by the ASTM standards themselves.
4. Adjudication Method for the Test Set
- Not Applicable. As this is mechanical testing against engineering standards, not a diagnostic assessment, there is no need for expert adjudication. The "adjudication" is inherent in the pass/fail criteria of the ASTM standards.
5. Multi-Reader, Multi-Case (MRMC) Comparative Effectiveness Study
- No. An MRMC study is not mentioned as this device is a physical implant, not an AI or diagnostic tool that assists human readers.
6. Standalone (Algorithm Only) Performance Study
- Not Applicable. This device is a physical implant, not an algorithm. Therefore, no standalone algorithm performance study was conducted.
7. Type of Ground Truth Used
- Engineering Standards/Material Properties. The ground truth for the device's performance is established by the specifications and pass/fail criteria defined within the ASTM F2077 (for intervertebral body fusion devices, static and dynamic compression) and ASTM F2267 (for intervertebral body fusion devices, subsidence) standards. These standards define the acceptable mechanical properties and behaviors for such implants.
8. Sample Size for the Training Set
- Not Applicable. This device is a physical product, not an AI model that requires a "training set."
9. How the Ground Truth for the Training Set Was Established
- Not Applicable. (See point 8).
Summary of the Study:
The L-Varlock Lumbar Cage underwent non-clinical mechanical testing to demonstrate that it meets established safety and performance standards for intervertebral body fusion devices. The study involved testing the physical device according to ASTM F2077 and ASTM F2267. These standards are designed to assess the static and dynamic compression behavior and subsidence characteristics of lumbar cages under simulated physiological loading conditions. The results indicated that the L-Varlock Lumbar Cages met the required mechanical acceptance criteria as defined by these ASTM standards. This type of testing is fundamental for demonstrating the structural integrity and mechanical suitability of physical implants before their use in humans.
{0}------------------------------------------------
K080537
Page 1 of 2
510(k) Summary for the L-Varlock Lumbar Cages
In accordance with 21 CFR 807.92 of the Federal Code of Regulations the following 510(k) summary is submitted for the L-Varlock Lumbar Cages
Date Prepared: February 20, 2008
| 1. Submitter: | Contact Person: |
|---|---|
| Kiscomedica | J.D. Webb |
| Parc Technologique | The OrthoMedix Group, Inc. |
| 2 Place Berthe Morisot | 1001 Oakwood Blvd |
| 69800 ST PRIEST | Round Rock, TX 78681 |
| FRANCE | Telephone: 512-388-0199 |
| 2. Trade name: | L-Varlock Lumbar Cages |
|---|---|
| Common Name: | intervertebral body fusion device |
| Classification Name: | intervertebral body fusion device |
| Class II per CFR Section 888.3080 | |
| MAX |
Predicate or legally marketed devices which are substantially equivalent: 3.
The L-Varlock Lumbar Cage is substantially equivalent to similar previously cleared lumbar intervertebral body fusion devices.
4. Description of the device:
L-Varlock Lumbar Cage is implanted via a posterior approach and supplemented by posterior fixation. Two devices are used. Main features of the L-Varlock lumbar cage are:
- Different heights for accurate enlargement of the foramina .
- Different widths and lengths to achieve excellent stability at the instrumented level . while preserving the patient's anatomy.
- Large graft space to achieve good bony fusion .
- Large cortical interface to ensure a good bony fusion. .
- Toothed outer walls prevent implant back out. ●
- The rounded geometry of the anterior end of the cage avoids damage to the anterior � vascular structures.
Materials:
L-Varlock lumbar Cages are manufactured from titanium alloy (Ti6Al4V-Eli, ASTM norm F136).
Function:
Lumbar interbody cages are one of the treatment options for low back pain.
5. Intended Use:
The L-Varlock Lumbar Cage is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s).
{1}------------------------------------------------
K080537
Page 2 of 2
L-Varlock Lumbar implants are to be used with autogenous bone graft and implanted via an open posterior approach. L-Varlock Lumbar implant is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.
Comparison of the technological characteristics of the device to predicate and legally marketed 6. devices:
The L-Varlock Lumbar Cage is similar to the predicate devices in terms of indications for use, design, material, and function.
7. Summary of Nonclincal Tests
Tests performed according to ASTM F2077/F2267 indicate that the L-Varlock Lumbar Cages meet the required mechanical acceptance criteria.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is an abstract image of an eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Kiscomedica % The OrthoMedix Group, Inc. Mr. J.D. Webb 1001 Oakwood Boulevard Round Rock, TX 78681
Re: K080537
Trade/Device Name: L-Varlock Lumbar Cage Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: May 27, 2008 Received: May 29, 2008
Dear Mr. Webb:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
JUN 3 0 2008
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - Mr. J.D. Webb
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mark M. Mulkerin
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
K080537
Page lot)
Indications for Use
K-08053 510(k) Number (if known):
Device Name: L-Varlock Lumbar Cage
Indications for Use:
The L-Varlock Lumbar Cage is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s).
L-Varlock Lumbar implants are to be used with autogenous bone graft and implanted via an open posterior approach. L-Varlock Lumbar implant is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.
Prescription Use _ X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of General, Restorative, and Neurological Devices
510(k) Number K086537
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.